•  
  •  
  •  
  •  

2025-10-03 12:19:46

  • Home
  • Commodities
  • Industry News
  • IPO
  • Mutual Funds
  • Others
  • Research
  • Watch List
Latest News
  • Black Box Partners with Wind River to Accelerate Edge and Cloud Innovation Globally
  • Godrej Properties ranked #1 amongst global residential developers for its ESG practices by GRESB
  • Union Minister Shri. Prahlad Joshi launches Refex Green Mobility Operations in Delhi NCR
  • IHC Expands Global Portfolio with USD 1Bn investment in Sammaan Capital
  • Revolt Motors Strengthens Leadership Team with Appointment of Raghava Rao as Chief Business Officer

Keywords Selected:  OphthalmicSolution

Stock Report

  • Gland Pharma receives approval from USFDA for Latanoprostene Bunod Opthalmic Solution
  • Glenmark receives ANDA approval for Olopatadine Hydrochloride Ophthalmic Solution USP, 0.2%
  • Caplin Steriles Ltd receives USFDA final approval for ANDA Brimonidine Tartrate and Timolol Maleate Ophthalmic Solution
  • Alembic Pharmaceuticals Ltd announces USFDA Tentative Approval for Olopatadine Hydrochloride Ophthalmic Solution USP, 0.7% (OTC)
  • Glenmark Pharmaceuticals Inc., USA launches Travoprost Ophthalmic Solution USP, 0.004%
  • Glenmark Therapeutics Inc., USA launches Olopatadine Hydrochloride Ophthalmic Solution USP, 0.1% OTC
  • Gland Pharma receives Tentative Approval from the USFDA for Latanoprostene Bunod Ophthalmic Solution
  • Alembic Pharmaceuticals announces USFDA Final Approval for Bromfenac Ophthalmic Solution, 0.07%
  • Lupin receives approval from U.S. FDA for Travoprost Ophthalmic Solution USP
  • Caplin Steriles gets USFDA approval for Ofloxacin Ophthalmic Solution
  • Caplin Steriles gets USFDA approval for Ketorolac Tromethamine Ophthalmic Solution
  • Lupin launches Bromfenac Ophthalmic Solution, 0.075% in the United States
  • Lupin Launches Bromfenac Ophthalmic Solution, 0.07% in the United States
  • Lupin receives approval from U.S. FDA for Bromfenac Ophthalmic Solution, 0.07%
  • Lupin receives approval from U.S. FDA for Bromfenac Ophthalmic Solution, 0.09%
  • Alembic Pharmaceuticals announces USFDA Final Approval for Brimonidine Tartrate Ophthalmic Solution, 0.15%

Latest Post

  • Black Box Partners with Wind River to Accelerate Edge and Cloud Innovation Globally
  • Godrej Properties ranked #1 amongst global residential developers for its ESG practices by GRESB
  • Union Minister Shri. Prahlad Joshi launches Refex Green Mobility Operations in Delhi NCR
  • IHC Expands Global Portfolio with USD 1Bn investment in Sammaan Capital
  • Revolt Motors Strengthens Leadership Team with Appointment of Raghava Rao as Chief Business Officer


Announcement

To Advertise in our website please e-mail us at advertisement@equitybulls.com
Companies can send their Press Releases to pressrelease@equitybulls.com

Links

  • Home
  • Contact
  • Our Team

Contact

The website is developed and maintained by Chennai Scripts
C-4, Podhigai Flats, Pillayar Koil Street, Nesapakkam
Chennai
Tamil Nadu
India
600078
E-mail: chennaiscripts@gmail.com
Mobile Phone Number: +91-88776-69935
www.chennaiscripts.com

Website Created & Maintained by : Chennai Scripts
Nesapakkam, Chennai - 600 078,
Tamil Nadu, India

Disclaimer Copyright © - 2024